Senior insider sale
Chief Financial Officer at MOONLAKE IMMUNOTHERAPEUTICS — senior position signals high conviction
$2.97M
160.87K shares
What this filing means
BODENSTEDT MATTHIAS plans to sell 160.87K shares of MOONLAKE IMMUNOTHERAPEUTICS valued at approximately $2.97M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 4/9/2026ACC: 0001969223-26-000438
Officer· Chief Financial Officer
Since Apr 2022
160.87K
Shares to sell
$2.97M
Approx. market value
160.87K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months2
Purchase
Cash
10/8/2025
10.87KExchange of share
Cash
4/5/2023
150KTotal acquired160.87K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
10/8/2025 | Purchase Cash | 10.87K | — |
4/5/2023 | Exchange of share Cash | 150K | — |
| Total | 160.87K | ||
Planned & Completed Dispositions1
NasdaqPlanned
Units to sell
160.87K
Market value
$2.97M
4/9/2026
Total
Units
160.87K
Value
$2.97M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
4/9/2026 | 160.87K | $2.97M | Nasdaq | Planned |
| Total | 160.87K | $2.97M | ||